{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:26:04Z","timestamp":1783481164868,"version":"3.55.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"the Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>MRSA is one of the main pathogens that cause nosocomial pneumonia. Based on longitudinal in vitro and in vivo data, a pharmacokinetic\u2013pharmacodynamic (PKPD) model was built to quantify the effect of two control antibiotics (LZD and VAN) for Gram-positive bacteria in a standardized mouse pneumonia model<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The PKPD model was developed for data generated on the MRSA strain 160\u200a079 in static in vitro time\u2013kill experiments and thereafter adjusted to fit data from lungs of neutropenic mice administered with single or multiple doses of LZD (0.5\u201340\u2005mg\/kg) or VAN (1\u201340\u2005mg\/kg). Simulations with human PK were run to predict antibacterial response in patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Bacterial regrowth observed in vitro when exposed to VAN concentrations was described by an adaptive resistance model. The selected MRSA isolate showed good virulence in the mouse pneumonia model. Bacterial load in lungs decreased up to 2-log with respect to control mice after LZD and VAN treatment. A 70%\u201375% lower killing rate was estimated for the in vivo data when compared with in vitro. Simulations displayed bacterial stasis at 24\u2005h for patients infected with bacteria with MICs below the clinical breakpoint for both drugs after administering standard-of-care dosing regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A translational workflow allowed us to build a PKPD model with both in vitro and in vivo data that characterized bacterial dynamics following LZD and VAN exposure, showing that this approach can inform the development of antibiotics. We also showcased the first successful use of the standardized mouse pneumonia model for Gram-positive bacteria.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf140","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:48:43Z","timestamp":1746805723000},"page":"1860-1868","source":"Crossref","is-referenced-by-count":5,"title":["Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant <i>Staphylococcus aureus<\/i>: from <i>in vitro<\/i> time\u2013kill experiments to a mouse pneumonia model"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9456","authenticated-orcid":false,"given":"Diego","family":"Vera-Yunca","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Matias","sequence":"additional","affiliation":[{"name":"Bacteria, Parasites & Fungi, Statens Serum Institut , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Vingsbo Lundberg","sequence":"additional","affiliation":[{"name":"Bacteria, Parasites & Fungi, Statens Serum Institut , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"2025070104564042900_dkaf140-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2025070104564042900_dkaf140-B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/microorganisms12010213","article-title":"Hospital-acquired pneumonia and ventilator-associated pneumonia: a literature review","volume":"12","author":"Miron","year":"2024","journal-title":"Microorganisms"},{"key":"2025070104564042900_dkaf140-B3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1055\/s-0041-1740583","article-title":"Methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia\/ventilator-associated pneumonia","volume":"43","author":"Pickens","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"2025070104564042900_dkaf140-B4","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.3390\/jcm12206526","article-title":"Ten issues to update in nosocomial or hospital-acquired pneumonia","volume":"12","author":"Candel","year":"2023","journal-title":"An Expert Review. J Clin Med"},{"key":"2025070104564042900_dkaf140-B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4939-9849-4_16","volume-title":"Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols: Cutting-Edge Technologies and Advancements","author":"Chalmers","year":"2020"},{"key":"2025070104564042900_dkaf140-B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2025070104564042900_dkaf140-B7","doi-asserted-by":"publisher","first-page":"988725","DOI":"10.3389\/fmicb.2022.988725","article-title":"Expert workshop summary: advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections","volume":"13","author":"Arrazuria","year":"2022","journal-title":"Front Microbiol"},{"key":"2025070104564042900_dkaf140-B8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025070104564042900_dkaf140-B9","doi-asserted-by":"publisher","first-page":"e0134822","DOI":"10.1128\/spectrum.01348-22","article-title":"Sequence type 5 (ST5) as a possible predictor of bacterial persistence in adult patients with methicillin-resistant Staphylococcus aureus pneumonia treated with vancomycin","volume":"10","author":"Fan","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025070104564042900_dkaf140-B10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antibiotics11060743","article-title":"Predicting antibiotic effect of vancomycin using pharmacokinetic\/pharmacodynamic modeling and simulation: dense sampling versus sparse sampling","volume":"11","author":"Kim","year":"2022","journal-title":"Antibiotics"},{"key":"2025070104564042900_dkaf140-B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","article-title":"Dosage regimen and toxicity risk assessment of linezolid in sepsis patients","volume":"96","author":"Dou","year":"2020","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"2025070104564042900_dkaf140-B12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00228-020-02978-x","article-title":"Prolonged infusion of linezolid is associated with improved pharmacokinetic\/pharmacodynamic (PK\/PD) profiles in patients with external ventricular drains","volume":"77","author":"Zhao","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2025070104564042900_dkaf140-B13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/cpt.2182","article-title":"Pivotal role of translation in anti-infective development","volume":"109","author":"Friberg","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025070104564042900_dkaf140-B14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025070104564042900_dkaf140-B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1128\/AAC.00694-11","article-title":"Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B16","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/jac\/dkw057","article-title":"A pharmacokinetic\u2013pharmacodynamic (PKPD) model based on in vitro time\u2013kill data predicts the in vivo PK\/PD index of colistin","volume":"71","author":"Khan","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025070104564042900_dkaf140-B17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/psp4.12197","article-title":"Translational pharmacometric evaluation of typical antibiotic broad-spectrum combination therapies against Staphylococcus aureus exploiting in vitro information","volume":"6","author":"Wicha","year":"2017","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2025070104564042900_dkaf140-B18","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1093\/jac\/dkae334","article-title":"Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus","volume":"79","author":"Saporta","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025070104564042900_dkaf140-B19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jac\/dkae409","article-title":"Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections","volume":"80","author":"Hern\u00e1ndez-Lozano","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025070104564042900_dkaf140-B20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025070104564042900_dkaf140-B21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cmi.2022.05.003","article-title":"Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia","volume":"28","author":"Aranzana-Climent","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025070104564042900_dkaf140-B22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/AAC.00604-06","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments","volume":"51","author":"Nielsen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B23","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1093\/jac\/dkw205","article-title":"A pharmacokinetic\u2013pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure","volume":"71","author":"Ungphakorn","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025070104564042900_dkaf140-B24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/infdis\/jiaa016","article-title":"Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis","volume":"223","author":"Bigelow","year":"2021","journal-title":"J Infect Dis"},{"key":"2025070104564042900_dkaf140-B25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3349\/ymj.2020.61.4.301","article-title":"Comparison of in vivo pharmacokinetics and pharmacodynamics of vancomycin products available in Korea","volume":"61","author":"Kim","year":"2020","journal-title":"Yonsei Med J"},{"key":"2025070104564042900_dkaf140-B26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients","volume":"56","author":"Minichmayr","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025070104564042900_dkaf140-B27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/cts.13210","article-title":"Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: pharmacokinetic model and model-informed precision dosing trial simulations","volume":"15","author":"Aljutayli","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025070104564042900_dkaf140-B28","volume-title":"VANCOCIN\u00ae HCl, Vancomycin Hydrochloride for Injection USP, For Intravenous Use","author":"Food and Drug Administration (FDA)"},{"key":"2025070104564042900_dkaf140-B29","volume-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 14.0","author":"EUCAST","year":"2024"},{"key":"2025070104564042900_dkaf140-B30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","article-title":"Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling","volume":"43","author":"Dosne","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025070104564042900_dkaf140-B31","volume-title":"A Tutorial on Visual Predictive Checks. Population Approach Group Europe","author":"Holford"},{"key":"2025070104564042900_dkaf140-B32","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team"},{"key":"2025070104564042900_dkaf140-B33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"2025070104564042900_dkaf140-B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2025070104564042900_dkaf140-B35","volume-title":"mrgsolve: Simulate from ODE-Based Models","author":"Baron","year":"2024"},{"key":"2025070104564042900_dkaf140-B36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/cpt1979253358","article-title":"Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine","volume":"25","author":"Sheiner","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"2025070104564042900_dkaf140-B37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jcpt.12123","article-title":"Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation","volume":"39","author":"Lim","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2025070104564042900_dkaf140-B38","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B39","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1128\/AAC.00633-09","article-title":"Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus","volume":"53","author":"Schmidt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","article-title":"Linezolid","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"2025070104564042900_dkaf140-B41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S0025-6196(12)65799-1","article-title":"Vancomycin","volume":"66","author":"Wilhelm","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"2025070104564042900_dkaf140-B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.vetmic.2016.05.006","article-title":"The pathogenicity and host adaptation of livestock-associated MRSA CC398","volume":"200","author":"Ballhausen","year":"2017","journal-title":"Vet Microbiol"},{"key":"2025070104564042900_dkaf140-B43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.pulmoe.2023.10.003","article-title":"Methicilin-susceptible Staphylococcus aureus clonal complex 398: an unusual agent of necrotizing pneumonia","volume":"30","author":"Nobre","year":"2024","journal-title":"Pulmonology"},{"key":"2025070104564042900_dkaf140-B44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/antibiotics4040521","article-title":"The impact on humans","volume":"4","author":"Cuny","year":"2015","journal-title":"Antibiotics"},{"key":"2025070104564042900_dkaf140-B45","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1128\/AAC.06121-11","article-title":"Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions","volume":"56","author":"Keel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B46","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"2025070104564042900_dkaf140-B47","doi-asserted-by":"publisher","first-page":"e00281-17","DOI":"10.1128\/AAC.00281-17","article-title":"Comparative pharmacodynamics of telavancin and vancomycin in the neutropenic murine thigh and lung infection models against Staphylococcus aureus","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B48","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1128\/AAC.00712-11","article-title":"Penetration of vancomycin into epithelial lining fluid in healthy volunteers","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104564042900_dkaf140-B49","doi-asserted-by":"publisher","first-page":"1702166","DOI":"10.1183\/13993003.02166-2017","article-title":"A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis","volume":"51","author":"Kempker","year":"2018","journal-title":"Eur Respir J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1860\/63138366\/dkaf140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1860\/63138366\/dkaf140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:56:53Z","timestamp":1751360213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/7\/1860\/8127977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,9]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf140","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,9]]}}}